Evidence map›Paper›PMID 41675050›Full record

ArticleiScience2026

Platelet membrane-camouflaged matrine biomimetic nanoparticles for efficient acute lung injury therapy.

Yinqiang Fan, Haiyuan Zhang, Xingxing Chai, Jiahao Liu, Yinlian Yao, Xin Shen, Ru Li, Ning Wei, Meiting Yang, Lixia Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yinqiang FanThe First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523808, China.
Haiyuan ZhangFeicheng People Hospital, Taian 271600, China.
Xingxing ChaiGuangdong Provincial Key Laboratory of Research and Development of Natural Drugs, School of Pharmacology, Laboratory Animal Center, Guangdong Medical University, Dongguan 523808, China.
Jiahao LiuGuangdong Provincial Key Laboratory of Research and Development of Natural Drugs, School of Pharmacology, Laboratory Animal Center, Guangdong Medical University, Dongguan 523808, China.
Yinlian YaoGuangdong Provincial Key Laboratory of Research and Development of Natural Drugs, School of Pharmacology, Laboratory Animal Center, Guangdong Medical University, Dongguan 523808, China.
Xin ShenGuangdong Provincial Key Laboratory of Research and Development of Natural Drugs, School of Pharmacology, Laboratory Animal Center, Guangdong Medical University, Dongguan 523808, China.
Ru LiThe First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523808, China.
Ning WeiThe First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523808, China.
Meiting YangThe First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523808, China.
Lixia LiThe First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523808, China.
Xiaolei ZhaoThe Key Laboratory of Medical Immunology and Molecular Diagnostics of Guangdong Province, Dongguan Key Laboratory of Medical Bioactive Molecular Developmental and Translational Research, Guangdong Medical University, Dongguan 523808, China.
Yue ZhaoThe First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523808, China.
Hua JinThe First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523808, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis frequently progresses to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), which are associated with high mortality. Current treatments face limitations due to resistance and toxicity. Matrine, a component of traditional Chinese medicine, exhibits anti-inflammatory properties but suffers from poor selectivity and potential toxicity. To address these challenges, this study developed platelet membrane-coated matrine nanoparticles (PM@Mat-NPs) for targeted ALI treatment. The PM@Mat-NPs, characterized by a particle size of ∼500 nm, zeta potential of -58 mV, and encapsulation efficiency of 82.1 ± 1.5%, effectively inhibited LPS-induced endothelial cell damage

Indexed as

biological sciencesBiomaterialsdrug delivery systemmaterials sciencenanoparticlespharmacologyTherapeutics

Identifiers

PMID41675050
PMCPMC12887251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.